No Data
The trading of major stocks may decrease, leading short-term funds to flow towards IPOs.
■ Since March 27 is the last day to hold rights for Dividends and benefits, interest is expected to turn towards Large Cap stocks in the Main Board, which may lead to a decrease in trading of key stocks in the Emerging Markets. On the other hand, the Growth Market 250 Index is clearly above the 25-day moving average, despite facing resistance at higher levels. It appears that a situation can be expected where attention is focused on the recent high of 693.92 points (February 13).
Announcement of individual stocks related to F351 and comments from the CEO.
An announcement is made regarding the scientific paper related to the liver fibrosis treatment candidate F351, developed by our group, which has been published in the Journal of Clinical and Translational Hepatology. The paper can be checked below. Comments from our CEO, Yin Luo: "The scientific paper titled 'Hydroni, a drug for the treatment of liver fibrosis associated with chronic hepatitis B,' was written by Professor Lungen Lu, the principal investigator of the F351 Phase 3 clinical trial."
Regarding the outlook for F351.
The initial estimate of 2 to 3 months was the best estimate based on our understanding of the data processing speed at that time. Subsequently, GYRE announced that it would be at the end of the first quarter of 2025. The most recent information disclosure on March 10 indicated that it was an estimate using industry standards, and no specific estimate for the F351 timeline was provided. Comparing the industry standard with the timeline disclosed by GYRE, the data processing for Peking Continent (BC) is clearly...
Due to the decline of major stocks, there is a possibility that the Growth Market 250 Index will reach a new low this year.
■Attention should be paid to the trends of the GN Group. In this week's Emerging Markets, the decline of the main stocks is further worsening investor sentiment, and there is a possibility that the Growth Market 250 Index may drop below the year's low of 624.73 points (closing basis) recorded on January 23. The trends of core 20 adopted stocks, such as GENDA <9166>, Cover <5253>, and Trial HD <141A>, which have a significant impact on the index, will attract attention. In particular, the decline in the Emerging Markets last week.
Regarding the publication of false information on the subsidiary company's website and the response to it.
From the night of March 7, 2025 (Friday) to the morning of March 8 (Saturday), fake news believed to be created by generative AI was posted on the website of our consolidated subsidiary, Peking Continental Pharmaceutical Co., Ltd. (hereinafter referred to as "Peking Continental"), which was later deleted by Peking Continental. In this regard, the following statement has been issued by Peking Continental. News of individual stocks – Peking Continental Pharmaceutical Co., Ltd. Peking Continental has made this statement.
Continued decline, influenced by statements from President Trump regarding tariff policies.
Overview for the week from March 3 to March 7 The Tokyo Stock Exchange Growth Index reached a high of 663.52 and a low of 631.01, closing at 631.01, a decline of 3.48% from the previous week. Continued decline was influenced by President Trump's remarks on tariff policies, resulting in fluctuations. Amidst the developments that caused both joy and concern due to Trump's statements, the drop in major stocks with large Market Cap led to a decline back to the levels seen in late January. Among the top Market Cap stocks are GNI Group <2160> and Attorney Dot Com <602.